{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:24:37Z","timestamp":1759530277339},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.clinthera.2012.06.004","type":"journal-article","created":{"date-parts":[[2012,6,22]],"date-time":"2012-06-22T21:18:35Z","timestamp":1340399915000},"page":"1592-1600","source":"Crossref","is-referenced-by-count":11,"title":["The Effect of Fimasartan, an Angiotensin Receptor Type 1 Blocker, on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Korean Male Volunteers: A One-Sequence, Two-Period Crossover Clinical Trial"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"nct00923533","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Namyi","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoung Soo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Seok","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seo Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo-Youn","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Goo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.06.004_bib1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/11593840-000000000-00000","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects","volume":"11","author":"Chi","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2012.06.004_bib2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.clinthera.2012.01.024","volume":"34","author":"Lee","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2012.06.004_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/08998280.2003.11927893","article-title":"Angiotensin II receptor blockers","volume":"16","author":"Barreras","year":"2003","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1016\/j.clinthera.2012.06.004_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/11533640-000000000-00000","article-title":"Fimasartan","volume":"11","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2012.06.004_bib5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/FJC.0b013e31822b9092","article-title":"The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers","volume":"58","author":"Shin","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.004_bib6","article-title":"Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin","author":"Kim","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.004_bib7","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/FJC.0b013e31821795d0","article-title":"Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers","volume":"57","author":"Yi","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.004_bib8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/FJC.0b013e318237389e","article-title":"Assessment of the drug-drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers","volume":"59","author":"Jeon","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.004_bib9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5414\/CP201533","article-title":"Effect of multiple doses of fimasartan, an angiotensin II receptor antagonist, on the steady-state pharmacokinetics of digoxin in healthy volunteers","volume":"49","author":"Yi","year":"2011","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2012.06.004_bib10","first-page":"476","article-title":"Warfarin\u2014indications, risks and drug interactions","volume":"39","author":"Tadros","year":"2010","journal-title":"Aust Fam Physician"},{"key":"10.1016\/j.clinthera.2012.06.004_bib11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/archinte.1994.00420030084008","article-title":"The international normalized ratio","volume":"154","author":"Hirsh","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2012.06.004_bib12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1517\/14740338.5.3.433","article-title":"Warfarin and its interactions with foods, herbs and other dietary supplements","volume":"5","author":"Nutescu","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clinthera.2012.06.004_bib13","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2012.06.004_bib16","first-page":"1765","article-title":"Comparative consistency between obesity determination standards using body mass index and ideal body weight","volume":"22","author":"Jung","year":"2001","journal-title":"J Korean Acad Fam Med"},{"key":"10.1016\/j.clinthera.2012.06.004_bib17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jpba.2006.05.025","article-title":"Supercritical fluid chromatography-tandem mass spectrometry for fast bioanalysis of R\/S-warfarin in human plasma","volume":"42","author":"Coe","year":"2006","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.clinthera.2012.06.004_bib18","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0731-7085(00)00232-6","article-title":"Validation of a method for the determination of (R)-warfarin and (S)-warfarin in human plasma using LC with UV detection","volume":"22","author":"Ring","year":"2000","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.clinthera.2012.06.004_bib19","series-title":"Pharmacokinetic and Pharmacodynamic Data Analysis, Concepts and Applications","author":"Gabrielsson","year":"2007"},{"key":"10.1016\/j.clinthera.2012.06.004_bib20","first-page":"81","article-title":"33rd Report, WHO Technical Report Series 687","year":"1983"},{"key":"10.1016\/j.clinthera.2012.06.004_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1055\/s-0037-1615004","article-title":"International collaborative study for the calibration of a proposed reference preparation for thromboplastin, human recombinant, plain","volume":"79","author":"Tripodi","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2012.06.004_bib22","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00228-008-0534-2","article-title":"Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects","volume":"64","author":"Almeida","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.004_bib23","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/0091270006291622","article-title":"Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men","volume":"46","author":"Soon","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.004_bib24","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1161\/01.CIR.0000063575.17904.4E","article-title":"American Heart Association\/American College of Cardiology Foundation guide to warfarin therapy","volume":"107","author":"Hirsh","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2012.06.004_bib25","series-title":"Pharmacokinetics in Drug Development","author":"Bonate","year":"2004"},{"key":"10.1016\/j.clinthera.2012.06.004_bib26","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/0091270004264164","article-title":"Absence of a pharmacokinetic interaction between etanercept and warfarin","volume":"44","author":"Zhou","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.004_bib27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2125.2005.02322.x","article-title":"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects","volume":"59","author":"Jiang","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.004_bib28","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1592\/phco.28.7.895","article-title":"Evaluation of a potential tigecycline-warfarin drug interaction","volume":"28","author":"Zimmerman","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2012.06.004_bib29","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1331\/JAPhA.2010.10531","article-title":"Science snippets","volume":"50","author":"Ried","year":"2010","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.clinthera.2012.06.004_bib30","doi-asserted-by":"crossref","first-page":"546S","DOI":"10.1378\/chest.08-0678","article-title":"Antithrombotic Therapy in Atrial Fibrillation: Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Singer","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2012.06.004_bib31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00228-005-0986-6","article-title":"Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects","volume":"61","author":"Jindal","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.004_bib32","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1046\/j.1365-2125.2002.01587.x","article-title":"Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin","volume":"53","author":"Dingemanse","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.004_bib33","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1023\/A:1010904815275","article-title":"Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin","volume":"18","author":"Miller","year":"2001","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2012.06.004_bib34","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1517\/17425255.2011.618835","article-title":"Effect of age on the pharmacokinetics of fimasartan (BR-A-657)","volume":"7","author":"Lee","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812003670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812003670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T06:21:19Z","timestamp":1561875679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812003670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0149291812003670"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.06.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}